Filed Pursuant to Rule 424(b)(3)
Registration Nos. 333-252073 and 333-249558
PROSPECTUS SUPPLEMENT NOS. 3 AND 2
(to Prospectuses
dated June 25, 2021 and June 25, 2021)
Clover Health Investments, Corp.
This prospectus supplement updates and supplements the prospectuses dated June 25, 2021 and June 25, 2021 (the
Prospectuses), which form a part of our registration statements on Form S-1 (No. 333-252073 and 333-249558,
respectively) (the Registration Statements). This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our current report on Form
8-K, filed with the Securities and Exchange Commission on July 22, 2021 (the Report). Accordingly, we have attached the Report to this prospectus supplement.
Our Class A common stock and public warrants are listed on the Nasdaq Global Select Market under the symbols CLOV and
CLOVW, respectively. On August 11, 2021, the last reported sales price of our Class A common stock was $8.13 per share and the last reported sales price of our public warrants was $2.02 per warrant.
This prospectus supplement should be read in conjunction with the Prospectuses. This prospectus supplement updates and supplements the
information in the Prospectuses. If there is any inconsistency between the information in either of the Prospectuses and this prospectus supplement, you should rely on the information in this prospectus supplement.
This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectuses.
We are an emerging growth company as defined in Section 2(a) of the Securities Act of 1933, as amended, and, as such, have
elected to comply with certain reduced disclosure and regulatory requirements.
Investing
in our securities involves risks. See the section entitled Risk Factors in each of the Prospectuses, and under similar headings in any further amendments or supplements to the Prospectuses, to read about factors you should consider
before buying our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus supplement or the Prospectuses is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is August 12, 2021.